They aren't just "pandemic stocks." ...

Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...

Pfizer has reached a turning point.

Pfizer Inc (NYSE:PFE) develops medicines and vaccines across multiple therapeutic areas, contributing to the S&P 500 ...

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s latest stock calls as he discussed the bullish AI investment thesis amid the ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Pfizer gets you most of the way to 10%. If you buy Pfizer and collect that 6.4% dividend yield, you are roughly two-thirds of the way toward the 10% return that most investors exp ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 31 trades. If we consider the specifics of each trade ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

Pfizer Inc. (NYSE: PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regimen demonstrated a statistically ...